Guriqbal Basi
2017
In 2017, Guriqbal Basi earned a total compensation of $2.4M as Senior Vice President, Chief Scientific Officer at Sarepta Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $72,800 |
|---|---|
| Option Awards | $2,173,910 |
| Salary | $105,000 |
| Other | $14,338 |
| Total | $2,366,048 |
Basi received $2.2M in option awards, accounting for 92% of the total pay in 2017.
Basi also received $72.8K in non-equity incentive plan, $105K in salary and $14.3K in other compensation.
Rankings
In 2017, Guriqbal Basi's compensation ranked 4,697th out of 14,666 executives tracked by ExecPay. In other words, Basi earned more than 68.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,697 out of 14,666 | 68th |
Division Manufacturing | 1,656 out of 5,768 | 71st |
Major group Chemicals And Allied Products | 482 out of 2,074 | 77th |
Industry group Drugs | 372 out of 1,730 | 79th |
Industry Pharmaceutical Preparations | 294 out of 1,329 | 78th |
Source: SEC filing on April 26, 2018.
Basi's colleagues
We found six more compensation records of executives who worked with Guriqbal Basi at Sarepta Therapeutics in 2017.
2017
Douglas Ingram
Sarepta Therapeutics
Chief Executive Officer
2017
Edward Kaye
Sarepta Therapeutics
Chief Executive Officer
2017
Alexander Cumbo
Sarepta Therapeutics
Senior Vice President, Chief Commercial Officer
2017
Sandesh Mahatme
Sarepta Therapeutics
Chief Financial Officer
2017
David Howton
Sarepta Therapeutics
General Counsel
2017
Catherine Stehman-Breen
Sarepta Therapeutics